Akero Therapeutics Inc (AKRO) - News Archive

Recent presentations by Akero Therapeutics and HistoIndex at the 2025 EASL Congress have brought forward significant advancements in the understanding and assessment of liver fibrosis, specifically in the context of the...

Akero Therapeutics Pushes Boundaries in Cirrhosis Treatment: Updates from SYMMETRY and SYNCHRONY Trials In an era where the implications of metabolic liver diseases are becoming increasingly pressing, Akero Therapeutics...

Akero Therapeutics Completes Robust Public Offering, Reinforcing Commitment to Transformational Metabolic Disease SolutionsSOUTH SAN FRANCISCO, Calif. January 30, 2025 In a significant move amidst a backdrop of promisin...

On January 28, 2025, Akero Therapeutics, Inc. (Nasdaq: AKRO), a pioneering clinical-stage enterprise dedicated to the development of innovative therapies for serious metabolic diseases, announced the pricing of an upsiz...

Akero Therapeutics Presents Promising Results from Phase 2b HARMONY Study at AASLD The Liver Meeting 2024 Akero Therapeutics has recently announced its decision to present new insights from its Phase 2b HARMONY study at...

In recent years, the burden of metabolic dysfunction-associated steatohepatitis (MASH) has risen significantly, necessitating the development of innovative therapeutics. Akero Therapeutics, a clinical-stage biopharmaceu...

Akero Therapeutics, Inc. has recently announced the successful closing of its underwritten public offering of common stock, along with the full exercise of underwritersn option to purchase additional shares. This clinic...

Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and liver cell damage, often leading to fibrosis, cirrhosis, and even hepatocellular carcinoma. With the increasing preva...

Akero Therapeutics Embarks on $300 Million Public Offering as It Advances in the Transformational Treatment of Metabolic DiseasesSOUTH SAN FRANCISCO, Calif., March 04, 2024 - Akero Therapeutics, a leading clinical-stage...

Akero Therapeutics Reports Significant Histological Improvements in Phase 2b HARMONY Study at Week 96Akero Therapeutics, a leading biotechnology company, recently released a press release highlighting the encouraging re...

eagerly awaits the release of topline Week 96 results from the Phase 2b HARMONY study, being conducted by Akero Therapeutics. This study focuses on investigating the potential of efruxifermin as a treatment for patients...

In a significant development for the field of nonalcoholic steatohepatitis (NASH) treatment, Akero Therapeutics has recently announced the dosing of the first patients in their Phase 3 SYNCHRONY Program for efruxifermin...